中国医学创新目次甘露聚糖肽与地榆升白片治疗白细胞减少症GD患者临床疗效对比研究(1)

http://www.100md.com 2018年1月15日 中国医学创新 2018年第2期

     【摘要】 目的：評价口服甘露聚糖肽与地榆升白片在毒性弥漫性甲状腺肿(GD)患者药物治疗所致白细胞(WBC)减少症的有效性及安全性。方法：选取本院抗GD治疗药物所致WBC减少症患者112例，按随机数字表法将其分为观察组和对照组，各56例，其中在研究过程中，观察组因患者移居外地而脱落4例。观察组口服甘露聚糖肽胶囊，对照组口服地榆升白片，60 d为1个治疗周期，停药后随访观察1个月。比较两组临床疗效、安全性(不良反应和复发情况)、治疗前后的WBC总数和中性粒细胞数。结果：观察组总有效率为94.23%，高于对照组的67.85%，比较差异有统计学意义( 字2=11.973，P=0.001)。治疗后，两组WBC总数、中性粒细胞数均高于治疗前，且观察组均高于对照组，比较差异均有统计学意义(P<0.05)。观察组不良反应发生率为17.31%，低于对照组的21.43%，比较差异无统计学意义(P>0.05)。停药后的随访观察中，观察组复发率为18.37%(9/49)，对照组为42.86%(21/49)，比较差异有统计学意义(P<0.05)。结论：两组药物均能显著升高因使用抗GD药物所致WBC减少症患者外周血WBC，甘露聚糖肽对WBC升高的幅度及安全性均优于地榆升白片。
, http://www.100md.com
    【关键词】 地榆升白片； 甘露聚糖肽； 毒性弥漫性甲状腺肿； 白细胞减少症

    【Abstract】 Objective：To evaluate the efficacy and safety of Mannatide and Diyushengbai Tablets in Treatment of Leukopenia in Graves disease(GD) patients.Method：A total of 112 patients with Leukopenia in GD in our hospital were selected，according to the random digital table method，they were divided into the observation group and control group，56 cases in each group，in the course of the study，the observation group dropped out of 4 cases because the patients moved out of the field.The observation group was treated with Mannatide Capsules，and control group was treated with Diyushengbai Tablets，60 d for 1 cycle，they were followed up for 1 month after drug withdrawal.The clinical efficacy，safety(adverse reaction and recurrence)，the total number of WBC and the number of neutrophils before and after treatment between two groups were compared.Result：The total effective rate of observation group was 94.23%，which was higher than 67.85% of control group，the difference was statistically significant( 字2=11.973，P=0.001).After treatment，the total number of WBC and neutrophils in two groups were all higher than those of before treatment，and observation group were higher than those of control group，the differences were statistically significant(P<0.05).The incidence of adverse reactions in observation group was 17.31%，which was lower than 21.43% of control group，the difference was not statistically significant(P>0.05).The recurrence rate of observation group was 18.37%(9/49)，and control group was 42.86%(21/49)，the difference was statistically significant(P<0.05).Conclusion：They can significantly increase the peripheral blood WBC of patients using GD drugs caused leukopenia，and the amplitude of WBC rise and safety of Mannatide is better than that of Diyushengbai Tablets.

    【Key words】 Diyushengbai Tablets； Mannatide； Graves disease； Leukopenia

    First-author’s address：The 202 Hospital of PLA，Shenyang 100001，China, 百拇医药(高伟)

第 1 2 3 页 下一页

    百拇医药网 http://www.100md.com/html/paper/1674-4985/2018/02/13.htm